Glioblastoma is notorious for its aggressive nature and poor patient survival, with standard-of-care treatments rarely extending life beyond 14 to 16 months post-diagnosis. The heterogeneity of this malignancy, compounded by molecular subtypes resistant to existing chemotherapy agents, underscores the urgent need for innovative treatment modalities. Recognizing this, the research team embarked on a mission to dissect the molecular underpinnings of glioblastoma’s resilience. They identified the myosin motor proteins—fundamental components that convert chemical energy into mechanical forces within cells—as key facilitators in tumor expansion and resistance mechanisms.

Myosin motors operate within a cellular environment much like miniature machines, orchestrating diverse processes such as motility, shape change, and intracellular transport. Their critical involvement in muscle cells is well-known, but their role in pathological states, including cancer progression, has remained largely unexploited due to the scarcity of selective pharmacological inhibitors. This gap presented both a challenge and an opportunity. By engineering a suite of small-molecule inhibitors capable of selectively incapacitating myosin motors involved in glioblastoma pathology, the team aimed to disrupt the cancer’s cellular machinery at a fundamental level.

The medicinal chemistry efforts, helmed by Dr. Theodore Kamenecka in collaboration with structural biologist Dr. Patrick Griffin, culminated in the synthesis of MT-125, a molecule specifically designed to inhibit non-muscle myosin II (NMII) functions within malignant cells. Early experimental models revealed that MT-125 impedes the contractile forces that cancer cells deploy to invade adjacent brain tissue, effectively "locking" them in place. This biophysical blockade stifles the tumor’s notorious ability to infiltrate and colonize new niches within the brain, which is a primary factor contributing to patient mortality.

A hallmark discovery in the research was MT-125’s ability to convert glioblastoma cells from radiation-resistant phenotypes into radiation-sensitive ones. Treated cells exhibited multinucleation—a condition where cells fail to undergo proper division and become marked for programmed cell death. This mechanistic insight was corroborated through murine models, where MT-125, both as a monotherapy and in combination with the kinase inhibitor sunitinib, elicited dramatic tumor regressions. These findings suggest a synergistic augmentation of existing chemotherapeutic regimens, opening avenues for combinatorial therapies with enhanced potency.

Despite the promising outcomes, the researchers caution against premature extrapolation to human clinical success. The biological divergence between murine models and human patients necessitates cautious optimism, with comprehensive toxicity profiling and dosing strategies integral to future studies. Notably, MT-125 displays preferential toxicity towards cancer cells over healthy tissue and possesses a pharmacokinetic profile suitable for pulsed administration, which may mitigate adverse effects commonly associated with chemotherapy.

The therapeutic significance of targeting molecular motors extends beyond glioblastoma. The science behind MT-125 opens a new frontier where disabling the mechanical underpinnings of malignant cells can be harnessed across a spectrum of cancers, potentially transforming treatment paradigms. Such a strategy veers away from traditional methods that primarily target genetic signals, focusing instead on the biophysical mechanisms essential to tumor progression.

In parallel with their oncology research, the team is advancing a related compound, MT-110, which holds promise in addressing methamphetamine use disorder by modulating myosin motor-driven neuronal pathways associated with drug craving. This illustrates the broad therapeutic potential of myosin motor inhibitors, resonating beyond cancer treatment to neurological and psychiatric diseases.

The pathway to bringing MT-125 from bench to bedside is well underway. The compound has been licensed to Myosin Therapeutics, a biotechnology startup founded by the principal investigators. With FDA approval granting clearance to initiate clinical trials, the team anticipates enrolling glioblastoma patients within the year. Substantial funding from the National Institutes of Health and dedicated glioblastoma research endowments supports this ambitious effort, laying the foundation for translational success.

Clinical trials will critically evaluate safety, dosing regimens, and efficacy in the complex and heterogeneous landscape of human glioblastoma. If successful, MT-125 could herald a new era where intractable brain tumors are rendered vulnerable to existing therapies, dramatically improving patient outcomes that have remained stagnant for decades.

This landmark research embodies the impact of interdisciplinary collaboration—melding medicinal chemistry, structural biology, neuro-oncology, and clinical expertise—to tackle one of the most formidable challenges in cancer treatment. By reimagining glioblastoma therapy through the lens of cellular mechanics, the scientists have illuminated a transformative therapeutic axis poised to advance the future of oncology.

Subject of Research: Animals

Article Title: Scientists wipe out aggressive brain cancer tumors by targeting cellular ‘motors’

News Publication Date: 1-Jul-2025

Web References:

• Research article in Cell: https://www.cell.com/cell/fulltext/S0092-8674(25)00569-0
• DOI link: http://dx.doi.org/10.1016/j.cell.2025.06.006

Image Credits: Image courtesy Steven Rosenfeld, M.D., Ph.D., and Courtney Miller, Ph.D.

Keywords: Glioblastomas, Brain cancer, Cancer

Glioblastoma stem cells represent a formidable challenge due to their ability to survive current therapeutic regimens and subsequently regenerate tumors, leading to inevitable relapse. Unlike the bulk tumor cells that may respond to surgery and chemoradiation, these stem-like cells exhibit remarkable adaptability and resistance. Dr. Samy Lamouille, an assistant professor at the Fralin Biomedical Research Institute and the lead author of this study, emphasizes the significance of targeting this cancer cell subpopulation, highlighting that their dormancy and later reactivation underline their critical role in tumor recurrence. The novel JM2 peptide therapy is designed specifically with this problem in mind.

The key to this innovative approach lies in the molecular interaction between connexin 43, a protein traditionally known for its role in forming gap junctions allowing cell-to-cell communication, and the cytoskeletal microtubules within glioblastoma stem cells. Using super-resolution microscopy, Dr. Lamouille and his collaborators unraveled an intricate association where connexin 43 decorates microtubules along their entire length within these malignant stem-like cells. This discovery reveals a heretofore unknown intracellular function of connexin 43 that supports the survival and tumorigenic capacity of glioblastoma stem cells.

This pivotal insight informed the design of JM2, a peptide derived from the microtubule-interacting domain of connexin 43. JM2 acts by disrupting this critical protein-microtubule interaction selectively within glioblastoma stem-like cells. Remarkably, while it interferes with this specific pathological mechanism, JM2 spares the other vital physiological roles of connexin 43, minimizing potential off-target effects. This selectivity underscores JM2’s therapeutic potential by efficiently targeting cancerous cells while leaving healthy brain tissue unharmed.

JM2 was initially developed by Dr. Rob Gourdie and his team at the Medical University of South Carolina, in collaboration with the Virginia Tech researchers. Preliminary experiments led by Dr. Lamouille’s lab demonstrated JM2’s impressive ability to induce cell death specifically in glioblastoma stem-like cells in vitro. The experimental data showed that JM2 significantly shrinks three-dimensional gliospheres—clusters of stem-like tumor cells grown in culture—suggesting potent tumoricidal effects intrinsic to the peptide.

Further in vivo studies strengthened these findings by revealing that JM2 substantially suppresses tumor growth in animal models. This effect is particularly important, as it offers tangible evidence that targeting connexin 43-microtubule interactions can impair the maintenance and tumorigenicity of glioblastoma stem cells in a manner that could be translatable to clinical therapy. It also represents a potential paradigm shift in glioblastoma treatment strategies, shifting the focus from bulk tumor eradication to directly targeting the root cause of recurrence.

The research excavates a previously unappreciated role of connexin 43 in cancer biology. Traditionally viewed as a tumor suppressor or facilitator depending on its location and expression levels, connexin 43’s interaction with microtubules in the cytoplasm appears to support the maintenance of glioblastoma stem cells. JM2’s mechanism of action injects fresh momentum into the study of connexin proteins as complex molecules with dualistic roles in cancer progression and treatment resistance.

This work also highlights the synergy between advanced imaging technologies, such as super-resolution microscopy, and molecular biology. The ability to visualize nanoscale protein arrangements within cancer cells provided the experimental window necessary to uncover the connexin 43-microtubule relationship. These technical advances empower researchers to reveal new targets and therapeutic avenues that were previously unreachable, potentially accelerating translational cancer research in the near future.

Moreover, the interdisciplinary collaboration between Virginia Tech’s Fralin Biomedical Research Institute and Carilion Clinic exemplifies the integration of basic science and clinical resources. Access to glioblastoma cells derived from consenting patients treated by Carilion physicians enabled cutting-edge experimental setups that closely mimic human disease conditions. This translational research model fosters innovations aimed at real-world clinical challenges, including the urgent need to tackle glioblastoma’s notorious treatment resistance and recurrence.

While JM2’s promise is robust in preclinical settings, the pathway towards human application will require extensive further research. Future efforts will focus on optimizing delivery mechanisms to guide JM2 precisely to glioblastoma cells, enhancing its therapeutic index. Investigators are exploring biodegradable nanoparticles and viral vector systems as potential carriers that could selectively release JM2 within tumor microenvironments, minimizing systemic exposure and side effects.

Importantly, Lamouille and Gourdie have co-founded Acomhal Research Inc., a start-up licensing the JM2 peptide with the goal of developing new targeted therapies for cancer patients. This commercialization step reflects the translational potential of fundamental discoveries from academic research to clinically viable treatments, aiming to bring hope to patients facing this devastating brain cancer.

In summary, the discovery and development of the JM2 peptide signify a landmark advance in glioblastoma research. By elucidating and targeting the novel role of connexin 43-microtubule interactions in glioblastoma stem cell biology, this work opens an unprecedented therapeutic window. The selective toxicity of JM2 towards resistant cancer stem-like cells while sparing normal brain cells underscores its potential as a groundbreaking peptide-based therapeutic. If successful in clinical translation, JM2 could transform glioblastoma treatment paradigms, improving survival and quality of life for countless patients globally.

Subject of Research: Cells

Article Title: Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicity

News Publication Date: 16-May-2025

Web References: https://doi.org/10.1038/s41419-025-07514-2

Image Credits: Samy Lamouille/Virginia Tech

Keywords: Health and medicine, Medical treatments, Biomedical engineering, Glioblastomas, Cancer

Recent clinical trial results, spearheaded by researchers at UT Health San Antonio, indicate that this investigational drug formulation more than doubles the median survival rates and disease progression-free intervals for glioblastoma patients compared to existing therapies. These remarkable findings were presented by Dr. Andrew J. Brenner, a prominent neuro-oncology researcher and the trial’s lead investigator, marking a significant step forward in the ongoing battle against this lethal disease.

Dr. Brenner emphasized the critical need for innovative treatments in glioblastoma, a cancer with a pattern of recurrence and resistance to existing chemotherapy options. He stated, "This trial provides hope, with a second phase under way and planned for completion by the end of this year." Such treatments should not only effectively target tumor cells but also minimize damage to healthy surrounding tissues, addressing a crucial concern in cancer therapy.

The study, titled "Convection Enhanced Delivery of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: a multicenter, single arm, phase 1 clinical trial," was released in the esteemed journal Nature Communications. It chronicles the findings from a trial that investigated the safety, tolerability, and efficacy of Rhenium Obisbemeda in patients who had previously undergone one to three different therapy protocols, including surgery, radiation, and chemotherapy.

Among the trial’s insights was the delivery mechanism employed for Rhenium Obisbemeda. The drug leverages specialized liposomes—nano-sized vesicles used to encapsulate drugs—allowing high doses of a radioactive isotope, rhenium-186, to be delivered directly to the tumor site. This innovative method prioritizes targeted therapy, which may significantly enhance drug effectiveness while reducing the risk of side effects typically associated with systemic treatments.

The trial unfolded over a period extending from March 5, 2015, to April 22, 2021, during which 21 patients were treated with Rhenium Obisbemeda via sophisticated neuronavigation and convection catheter delivery systems. These advancements in medical technology were crucial in enabling precise and effective application of the treatment directly to the tumor, thus improving patient outcomes.

Promisingly, the data highlighted a significant survival benefit, particularly for those patients receiving higher doses of the drug. For those treated with doses exceeding 100 gray, the median survival time surged to an impressive 17 months with a progression-free interval of 6 months. These findings contrast starkly with the average survival rate of approximately 8 months following standard treatment failures, demonstrating a profound impact on patient may experience.

Moreover, the research team did not observe any dose-limiting toxic effects associated with the treatment, a notable achievement in the realm of oncology where side effects often complicate the treatment landscape. Most adverse effects reported by participants were deemed unrelated to the investigational agent, lending further credence to the safety profile of Rhenium Obisbemeda.

In closing, Dr. Brenner remarked on the technological synergy at play in this trial: "The combination of a novel nanoliposome radiotherapeutic delivered by convection-enhanced delivery, facilitated by neuronavigational tools, catheter design, and imaging solutions, can successfully and safely provide high absorbed radiation doses to tumors with minimal toxicity and potential survival benefit." Such advances not only represent a significant milestone in glioblastoma treatment but also pave the way for future research and development in targeted cancer therapies.

As the second phase of the ReSPECT-GBM trial commences with active patient enrollment, there is persistent optimism within the scientific community and among patients as well. The potential of Rhenium Obisbemeda to emerge as a transformative treatment underscores the imperative of continuing research efforts and collaborative trials aimed at conquering the challenges posed by glioblastoma and other complex cancers. The future of glioblastoma treatment may well look brighter, thanks to the trajectory set into motion by this cutting-edge research collaboration.

The advances brought about by this research at UT Health San Antonio exemplify the ongoing commitment within the scientific community to innovate and develop therapies that offer better outcomes for patients grappling with the harsh realities of cancer. As the reach of Rhenium Obisbemeda expands, it holds the promise of reshaping standards of care in neuro-oncology.

Research collaborations involving prestigious institutions further strengthen the credibility and potential of this treatment, highlighting the importance of multidisciplinary approaches in tackling complex health challenges. In reflecting on these developments, it is clear that the fight against glioblastoma is far from over, and with each breakthrough comes renewed hope and a lived testament to the resilience of those affected by this formidable disease.

Subject of Research: Glioblastoma Treatment
Article Title: Convection Enhanced Delivery of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: a multicenter, single arm, phase 1 clinical trial
News Publication Date: March 7, 2025
Web References: Nature Communications DOI
References: Not applicable
Image Credits: Not applicable

Keywords: Glioblastomas, Drug studies, Clinical research, Cancer patients, Radiation therapy, Drug research, Brain tumors, Gliomas